Twitter LinkedIn
Return to Wellspring

Projects Sharing Researchers

Communicate

Acute Megakarocytic Leukemia (AMKL) Treatment

Details

Project TitleAcute Megakarocytic Leukemia (AMKL) Treatment
Track Code2008-077
Short Description

New approach for treating AMKL by inducing polyploidization to revert cancerous cells into normal cells

#therapeutics #cancer # smallmolecules

Abstract

A unique therapeutic approach for acute megakaryocytic leukemia (AMKL) has been developed at Northwestern University. AMKL is an aggressive form of blood cancer for which there are few promising drug options. Based upon their identification of a unique feature of AMKL cells, Northwestern scientists developed an innovative treatment strategy. Cancerous megakaryocytic cells in AMKL sidestep a normal differentiation process called polyploidization. The screening method Prof. Crispino and colleagues designed may be used to search for compounds that would induce this process and render the cancerous cells normal. They believe this approach to chemotherapy may be less toxic to patients and would produce fewer side effects than standard chemotherapies, which eliminate both cancerous and healthy cells.

 
TagsTHERAPEUTICS: cancer, THERAPEUTICS: small molecule
 
Posted DateMay 5, 2015 1:04 PM

Inventor(s)

John Crispino*

Qiang Wen

Zan Huang

Robert Gould

Andrew Stern

Applications

  • Treatment of AMKL and other megakaryopoetic diseases
  • Research reagents for study of megakaryocytes

Advantages

  • Low chance of side-effects
  • Applicable to various megakaryopoetic disorders

Publications

IP Status

Issued US patent 8,993,071

Contact Information

Michael Moore, PhD

Invention Manager

(p) 847.491.4645

(e) michaelmoore@northwestern.edu